Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.61 |
| ▸ | CES1 | P23141 | 5/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701117 | 0.80 | CYP3A4 (0.43) | CES2CES1 | |
| SCHEMBL2466962 | 0.79 | CES2 (0.64) | CES2CES1EPHX1IDO1TDO2 | |
| SCHEMBL851355 | 0.79 | CES2 (0.63) | CES2CES1NR1I2TRPM8CA12 | |
| SCHEMBL1572839 | 0.79 | CES2 (0.63) | CES2CES1NR1I2TRPM8CA12 | |
| SCHEMBL1572867 | 0.79 | CES2 (0.63) | CES2CES1NR1I2TRPM8CA12 | |
| Hydrochloric Acid SCHEMBL7248837 | 0.77 | CES2 (0.61) | CES2CES1EIF2AK3CA12CA1 | |
| SCHEMBL14537114 | 0.77 | CES2 (0.61) | CES2CES1NR1I2TRPM8EIF2AK3 | |
| Hydrochloric Acid SCHEMBL7248840 | 0.77 | CES2 (0.61) | CES2CES1EIF2AK3CA12CA1 | |
| SCHEMBL8313497 | 0.77 | CES2 (0.61) | CES2CES1NR1I2TRPM8EIF2AK3 | |
| SCHEMBL19735013 | 0.77 | HDAC3 (0.45) | CES2CES1EPHX1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021893-A1 | PERK INHIBITING COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2021041973-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| US-12584105-B2 | Autologous cell replacement therapy for Parkinson's disease | THE MCLEAN HOSPITAL CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| EP-3212773-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | Massachusetts Eye & Ear Infirmary (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017096233-A1 | TREATMENT OF HEARING LOSS BY INHIBITION OF CASEIN KINASE 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2016069906-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20150209406-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-30 | — | — | US | disclosed |
| US-20150209367-A1 | Treating Hearing Loss | MASSACHUSETTS EYE & EAR INFIRMARY | 2015-07-30 | — | — | US | disclosed |
| EP-2892523-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | Massachusetts Eye & Ear Infirmary (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2892506-A1 | TREATING HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039781-A1 | TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039908-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | CES2 3619/4885CES1 600/4885NR1I2 1661/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | CES2 4842/4885CES1 4359/4885NR1I2 2037/4885 |
| US-20150209406-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | CES2 4629/4885CES1 4341/4885NR1I2 4248/4885 |
| US-12584105-B2 | Autologous cell replacement therapy for Parkinson's disease | SNCA, PARK7, NES | CES2 1593/4885CES1 4359/4885NR1I2 4424/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | CES2 1687/4885CES1 1194/4885NR1I2 2635/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | CES2 4675/4885CES1 4374/4885NR1I2 4256/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | CES2 4675/4885CES1 4374/4885NR1I2 4256/4885 |
| US-20150209367-A1 | Treating Hearing Loss | BACE1, BACE2, PSENEN | CES2 1687/4885CES1 1194/4885NR1I2 2635/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | CES2 4842/4885CES1 4359/4885NR1I2 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.